CLL11-studie: finale resultaten obinutuzumab versus rituximab

Delen via:
EHA 2018

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Goede V, Fischer K, Dyer MJS, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA 2018; abstract S151.